Cholangiocarcinoma Market Segmentation:
Distribution Channel
The retail pharmacy segment is anticipated to hold 40% share of the global cholangiocarcinoma market during the forecast period. The Cholangiocarcinoma (CCA) treatment market is predicted to continue growing because of the increasing availability of both prescription and over-the-counter medications in retail pharmacies. The convenience of being able to buy various medical supplies and fill several prescriptions in one location is probably a big reason why retail pharmacies are becoming more and more popular. Retail chains are the largest prescription distributors per retail location, dispensing over 138,000 prescriptions annually per store, or almost 50% more than grocers.
Cancer Type
Cholangiocarcinoma market from the intrahepatic cholangiocarcinoma segment is estimated to hold largest share of about 58% during the forecast period mainly due to the disease's rising global occurrence. Every year, about 8,000 Americans receive a diagnosis for it. Cholangiocarcinoma affects fewer than six persons per 100,000 in Western countries annually. But cholangiocarcinoma is more common in Southeast Asia, that is, Thailand, South Korea, and China, affecting over six persons out of every 100,000 annually. During the forecast period, the market is anticipated to increase due in part to the presence of several large and mid-sized pharmaceutical suppliers with novel medicines that are nearing the completion of clinical studies.
Our in-depth analysis of the global cholangiocarcinoma market includes the following segments:
|
Product Type |
|
|
Cancer Type |
|
|
Therapy Type |
|
|
Route of Administration |
|
|
Distribution Channel |
|
